Comparative effects of pranidipine with amlodipine in rats with heart failure

Punniyakoti T. Veeraveedu, Kenichi Watanabe, Meilei Ma, Narasimman Gurusamy, Suresh S. Palaniyandi, Juan Wen, Paras Prakash, Mir Imam Ibne Wahed, Fadia Kamal, Sayaka Mito, Megumi Kunisaki, Makoto Kodama, Yoshifusa Aizawa

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The aim of the present study was to compare the cardioprotective properties of long-acting calcium channel antagonist pranidipine with amlodipine in rat model of heart failure induced by autoimmune myocarditis. Twenty-eight days after immunization the surviving rats were randomized for the oral administration of low-dose amlodipine (1 mg/kg/day), high-dose amlodipine (5 mg/kg/ day), pranidipine (0.3 mg/kg/day) or vehicle (0.5% methylcellulose). After oral administration for 1 month, the animals underwent echocardiography and hemodynamic analysis. Histopathology, immunohistochemistry, and Western immunoblotting were carried out in the heart samples. Both pranidipine and high-dose amlodipine increased survival rate. Although the heart rate did not differ among the four groups, left ventricular end-diastolic pressure was significantly decreased and ± dP/dt was increased in the pranidipine- and high-dose amlodipine-treated rats, but not in low-dose amlodipine-treated rats. In comparison to amlodipine treatment, pranidipine treatment significantly reduced myocyte size and central venous pressure. Furthermore, both pranidipine and high-dose amlodipine treatment significantly reduced myocardial protein levels of atrial natriuretic peptide and inducible nitric oxide synthase, whereas pranidipine only significantly decreased tumor necrosis factor-α, and improved sarcoplasmic reticulum Ca2+ATPase2 protein levels. We conclude that pranidipine ameliorates the progression of left ventricular dysfunction and cardiac remodeling in rats with heart failure after autoimmune myocarditis in a lower dose when compared to amlodipine and which may be a clinically potential therapeutic agent for the treatment of heart failure.

Original languageEnglish (US)
Pages (from-to)1-10
Number of pages10
JournalPharmacology
Volume77
Issue number1
DOIs
StatePublished - May 1 2006

Fingerprint

Amlodipine
Heart Failure
Ventricular Remodeling
Myocarditis
Oral Administration
pranidipine
Central Venous Pressure
Methylcellulose
Calcium Channel Blockers
Sarcoplasmic Reticulum
Left Ventricular Dysfunction
Atrial Natriuretic Factor
Nitric Oxide Synthase Type II
Therapeutics
Treatment Failure
Muscle Cells
Echocardiography
Immunization
Proteins
Tumor Necrosis Factor-alpha

All Science Journal Classification (ASJC) codes

  • Pharmacology

Cite this

Veeraveedu, P. T., Watanabe, K., Ma, M., Gurusamy, N., Palaniyandi, S. S., Wen, J., ... Aizawa, Y. (2006). Comparative effects of pranidipine with amlodipine in rats with heart failure. Pharmacology, 77(1), 1-10. https://doi.org/10.1159/000091746
Veeraveedu, Punniyakoti T. ; Watanabe, Kenichi ; Ma, Meilei ; Gurusamy, Narasimman ; Palaniyandi, Suresh S. ; Wen, Juan ; Prakash, Paras ; Wahed, Mir Imam Ibne ; Kamal, Fadia ; Mito, Sayaka ; Kunisaki, Megumi ; Kodama, Makoto ; Aizawa, Yoshifusa. / Comparative effects of pranidipine with amlodipine in rats with heart failure. In: Pharmacology. 2006 ; Vol. 77, No. 1. pp. 1-10.
@article{8aa6c9e199d442259fcacc558d8cf891,
title = "Comparative effects of pranidipine with amlodipine in rats with heart failure",
abstract = "The aim of the present study was to compare the cardioprotective properties of long-acting calcium channel antagonist pranidipine with amlodipine in rat model of heart failure induced by autoimmune myocarditis. Twenty-eight days after immunization the surviving rats were randomized for the oral administration of low-dose amlodipine (1 mg/kg/day), high-dose amlodipine (5 mg/kg/ day), pranidipine (0.3 mg/kg/day) or vehicle (0.5{\%} methylcellulose). After oral administration for 1 month, the animals underwent echocardiography and hemodynamic analysis. Histopathology, immunohistochemistry, and Western immunoblotting were carried out in the heart samples. Both pranidipine and high-dose amlodipine increased survival rate. Although the heart rate did not differ among the four groups, left ventricular end-diastolic pressure was significantly decreased and ± dP/dt was increased in the pranidipine- and high-dose amlodipine-treated rats, but not in low-dose amlodipine-treated rats. In comparison to amlodipine treatment, pranidipine treatment significantly reduced myocyte size and central venous pressure. Furthermore, both pranidipine and high-dose amlodipine treatment significantly reduced myocardial protein levels of atrial natriuretic peptide and inducible nitric oxide synthase, whereas pranidipine only significantly decreased tumor necrosis factor-α, and improved sarcoplasmic reticulum Ca2+ATPase2 protein levels. We conclude that pranidipine ameliorates the progression of left ventricular dysfunction and cardiac remodeling in rats with heart failure after autoimmune myocarditis in a lower dose when compared to amlodipine and which may be a clinically potential therapeutic agent for the treatment of heart failure.",
author = "Veeraveedu, {Punniyakoti T.} and Kenichi Watanabe and Meilei Ma and Narasimman Gurusamy and Palaniyandi, {Suresh S.} and Juan Wen and Paras Prakash and Wahed, {Mir Imam Ibne} and Fadia Kamal and Sayaka Mito and Megumi Kunisaki and Makoto Kodama and Yoshifusa Aizawa",
year = "2006",
month = "5",
day = "1",
doi = "10.1159/000091746",
language = "English (US)",
volume = "77",
pages = "1--10",
journal = "Pharmacology",
issn = "0031-7012",
publisher = "S. Karger AG",
number = "1",

}

Veeraveedu, PT, Watanabe, K, Ma, M, Gurusamy, N, Palaniyandi, SS, Wen, J, Prakash, P, Wahed, MII, Kamal, F, Mito, S, Kunisaki, M, Kodama, M & Aizawa, Y 2006, 'Comparative effects of pranidipine with amlodipine in rats with heart failure', Pharmacology, vol. 77, no. 1, pp. 1-10. https://doi.org/10.1159/000091746

Comparative effects of pranidipine with amlodipine in rats with heart failure. / Veeraveedu, Punniyakoti T.; Watanabe, Kenichi; Ma, Meilei; Gurusamy, Narasimman; Palaniyandi, Suresh S.; Wen, Juan; Prakash, Paras; Wahed, Mir Imam Ibne; Kamal, Fadia; Mito, Sayaka; Kunisaki, Megumi; Kodama, Makoto; Aizawa, Yoshifusa.

In: Pharmacology, Vol. 77, No. 1, 01.05.2006, p. 1-10.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Comparative effects of pranidipine with amlodipine in rats with heart failure

AU - Veeraveedu, Punniyakoti T.

AU - Watanabe, Kenichi

AU - Ma, Meilei

AU - Gurusamy, Narasimman

AU - Palaniyandi, Suresh S.

AU - Wen, Juan

AU - Prakash, Paras

AU - Wahed, Mir Imam Ibne

AU - Kamal, Fadia

AU - Mito, Sayaka

AU - Kunisaki, Megumi

AU - Kodama, Makoto

AU - Aizawa, Yoshifusa

PY - 2006/5/1

Y1 - 2006/5/1

N2 - The aim of the present study was to compare the cardioprotective properties of long-acting calcium channel antagonist pranidipine with amlodipine in rat model of heart failure induced by autoimmune myocarditis. Twenty-eight days after immunization the surviving rats were randomized for the oral administration of low-dose amlodipine (1 mg/kg/day), high-dose amlodipine (5 mg/kg/ day), pranidipine (0.3 mg/kg/day) or vehicle (0.5% methylcellulose). After oral administration for 1 month, the animals underwent echocardiography and hemodynamic analysis. Histopathology, immunohistochemistry, and Western immunoblotting were carried out in the heart samples. Both pranidipine and high-dose amlodipine increased survival rate. Although the heart rate did not differ among the four groups, left ventricular end-diastolic pressure was significantly decreased and ± dP/dt was increased in the pranidipine- and high-dose amlodipine-treated rats, but not in low-dose amlodipine-treated rats. In comparison to amlodipine treatment, pranidipine treatment significantly reduced myocyte size and central venous pressure. Furthermore, both pranidipine and high-dose amlodipine treatment significantly reduced myocardial protein levels of atrial natriuretic peptide and inducible nitric oxide synthase, whereas pranidipine only significantly decreased tumor necrosis factor-α, and improved sarcoplasmic reticulum Ca2+ATPase2 protein levels. We conclude that pranidipine ameliorates the progression of left ventricular dysfunction and cardiac remodeling in rats with heart failure after autoimmune myocarditis in a lower dose when compared to amlodipine and which may be a clinically potential therapeutic agent for the treatment of heart failure.

AB - The aim of the present study was to compare the cardioprotective properties of long-acting calcium channel antagonist pranidipine with amlodipine in rat model of heart failure induced by autoimmune myocarditis. Twenty-eight days after immunization the surviving rats were randomized for the oral administration of low-dose amlodipine (1 mg/kg/day), high-dose amlodipine (5 mg/kg/ day), pranidipine (0.3 mg/kg/day) or vehicle (0.5% methylcellulose). After oral administration for 1 month, the animals underwent echocardiography and hemodynamic analysis. Histopathology, immunohistochemistry, and Western immunoblotting were carried out in the heart samples. Both pranidipine and high-dose amlodipine increased survival rate. Although the heart rate did not differ among the four groups, left ventricular end-diastolic pressure was significantly decreased and ± dP/dt was increased in the pranidipine- and high-dose amlodipine-treated rats, but not in low-dose amlodipine-treated rats. In comparison to amlodipine treatment, pranidipine treatment significantly reduced myocyte size and central venous pressure. Furthermore, both pranidipine and high-dose amlodipine treatment significantly reduced myocardial protein levels of atrial natriuretic peptide and inducible nitric oxide synthase, whereas pranidipine only significantly decreased tumor necrosis factor-α, and improved sarcoplasmic reticulum Ca2+ATPase2 protein levels. We conclude that pranidipine ameliorates the progression of left ventricular dysfunction and cardiac remodeling in rats with heart failure after autoimmune myocarditis in a lower dose when compared to amlodipine and which may be a clinically potential therapeutic agent for the treatment of heart failure.

UR - http://www.scopus.com/inward/record.url?scp=33646498957&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646498957&partnerID=8YFLogxK

U2 - 10.1159/000091746

DO - 10.1159/000091746

M3 - Article

VL - 77

SP - 1

EP - 10

JO - Pharmacology

JF - Pharmacology

SN - 0031-7012

IS - 1

ER -

Veeraveedu PT, Watanabe K, Ma M, Gurusamy N, Palaniyandi SS, Wen J et al. Comparative effects of pranidipine with amlodipine in rats with heart failure. Pharmacology. 2006 May 1;77(1):1-10. https://doi.org/10.1159/000091746